Sandoz launches new OMNITROPE growth hormone concentration in Egypt
Sandoz, a global leader in generic and biosimilar medicines, announced on Sunday the introduction of its 15mg/1.5ml concentration of the OMNITROPE biosimilar growth hormone to the Egyptian market for the treatment of short stature. This initiative aligns with Sandoz's ongoing efforts to support Egypt's Vision 2030 and local healthcare authorities' commitment to enhancing public health.
The company stated that the newly available concentration aims to help expand access to growth hormone, noting that an estimated 17% of Egyptian children suffer from short stature. Research conducted at Suez Canal University's endocrinology outpatient clinic, released in 2024, indicated that growth hormone treatment significantly improves physical, social, psychological, and environmental quality of life.
Dr. Mona Salem, Professor of Paediatric Endocrinology at Ain Shams University and President of the Egyptian Society of Paediatric Endocrinology & Diabetes, said: 'In children and adolescents, growth hormone is used to treat growth disturbance due to insufficient secretion of growth hormone, associated with Turner syndrome, with chronic renal insufficiency, in short children/adolescents born small for gestational age, or associated with Prader-Willi syndrome (PWS). The biosynthetic/synthetic hormone is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone (GH).'
Dr. Salem added, 'Short stature is diagnosed in children or adolescents who are well below the average height for their age and gender, which may be due to genetic factors or underlying health conditions. Studies show that short stature prevalence varies geographically, with a genetic predisposition, as well as nutritional and environmental factors, playing an important role.'
A cross-sectional study conducted between January 2018 and January 2020 involving 33,150 Egyptian children aged 6 to 11 showed that 17% of the sample had short stature, with 40.8% attributed to familial factors and 24.2% to constitutional causes.
Dr. Rasha Tarif, Head of the Paediatric Endocrinology Unit at Ain Shams University and Chair of the European Society for Paediatric Endocrinology (ESPE) Education and Training Committee, stated: 'As noted, short stature affects children and adolescents, not only physically but also psychologically. Growth hormone is one of the most effective treatments for the aforementioned growth disturbances. The dosage is carefully calculated based on weight, underlying cause, puberty stage, as well as stimulated growth hormone test results, to achieve the best possible final height outcomes.'
Dr. Tarif emphasised that young patients require therapeutic intervention before growth plates fuse, after which height cannot be gained. She added, 'Growth hormone plays a critical role in effective treatment plans, but ensuring its availability has been a challenge in recent years. This challenge is being addressed through ongoing efforts to secure sufficient quantities to ensure uninterrupted treatment until puberty is complete, and in some cases, for life. Treatment continuity, along with proper follow-up with a specialized physician, is essential for achieving optimal results.'
Sandoz said the new concentration is being made available at an affordable cost, expanding treatment options and aiming for better patient response and an effective, safe treatment journey by minimising interruptions. The company stated that securing the reliable availability of this human growth hormone reinforces medical efforts to provide comprehensive care.
Sameh Elbagoury, Sandoz Egypt Country Head, said: 'The Egyptian government, within the context of the Egypt Vision 2030, has shown strong commitment to reducing the prevalence of short stature among children, aiming to improve public health for current and future generations, and help build a healthier, more productive workforce, in line with the national vision for sustainable development.'
Elbagoury added: 'Our top priority at Sandoz is to develop affordable biosimilars for high-quality biologics and ensure that as many patients as possible have access to them. Introducing the 15mg concentration of our well-established Omnitrope growth hormone allows us to help local authorities meet the increase in demand for growth hormones, reflecting the positive impact and notable success achieved by the Presidential Initiative for the Early Detection of Anaemia, Obesity and Short Stature.'
Sandoz Omnitrope received approval from the US Food and Drug Administration and the European Medicines Agency in 2006, with subsequent approvals in other countries. Sandoz has also established a long-term, post-marketing surveillance programme for the product.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily News Egypt
9 hours ago
- Daily News Egypt
Haleon captures over 20% market share in Egypt, locally manufactures 90% of product portfolio
Haleon, the global consumer health leader, has reinforced its footprint in Egypt following its demerger from GSK in July 2022. The company now holds over 20% of Egypt's consumer health market and manufactures approximately 90% of its flagship brands locally, according to Asif Alavi, General Manager for North Africa at Haleon. Speaking to Daily News Egypt, Alavi said that local production covers trusted household names such as Sensodyne, Parodontax, Panadol, Otrivin, and Voltaren Emulgel, underscoring Haleon's commitment to supply chain resilience and economic contribution through technology transfer and export capabilities. Egypt serves as a key regional base for exports to the Maghreb, Gulf countries, and Saudi Arabia. Alavi emphasized that local manufacturing has helped shield the company from global economic volatility, including inflation, currency fluctuations, and supply chain disruptions. 'Our strategy has significantly minimized exposure to global shocks, enabling us to maintain stability and accessibility in the Egyptian market,' he noted. Globally, Haleon is advancing its innovation pipeline, including a £130m investment in a new Global Oral Health Innovation Centre in Weybridge, UK, slated to open in 2027. The facility will support Haleon's category leadership in oral health and accelerate R&D for key brands like Sensodyne, which Alavi described as resilient due to its therapeutic value and strong dentist recommendations—even during economic downturns. Recognizing the price sensitivity in emerging markets, Haleon has adopted a multi-format, tiered pricing strategy to ensure broad accessibility. The company also champions self-care as a cornerstone of sustainable healthcare. Alavi cited research by the Global Self-Care Federation, which estimates self-care interventions have already delivered $119bn in global healthcare cost savings and $1.9trn in welfare gains—figures projected to rise to $179bn and $2.8trn, respectively. Looking ahead, Alavi reaffirmed Haleon's long-term vision in Egypt: 'We are committed to being a core contributor to the Egyptian healthcare ecosystem—by making everyday health more accessible, inclusive, and sustainable.'
Mada
12 hours ago
- Mada
Politicians, students, 130 former prisoners call for Sisi to release Alaa Abd El Fattah immediately
Urgent appeals have mounted in the last hours for the immediate release of detained activist and writer, Alaa Abd El Fattah, as his mother Laila Soueif lies in hospital in London, 245 days into a hunger strike. Egyptian authorities have imprisoned Abd El Fattah since 2019, in what United Nations experts ruled last week is arbitrary detention. Among those calling for his release are nearly 130 former prisoners, all of whom faced similar charges to Abd El Fattah in relation to their political views, and who issued a statement on Saturday calling for the writer's release 'today, not tomorrow,' in a plea to 'end the suffering of his family and save the life of his mother.' Soueif's blood sugar dropped dangerously low on Thursday night and she was hospitalized. Doctors say her life is in immediate danger. The prisoners' statement was shared by activist Ahmed Douma, who spent a decade in prison for participating in protests before he was granted presidential amnesty in 2023, and by lawyer and activist Mahienour al-Massry who was detained in 2018 while advocating for the release of detainees imprisoned for their political convictions. All signatories to the appeal faced charges similar to Abd El Fattah's, the statement said, including spreading false news, unlawful assembly, joining a terrorist group 'or other charges tied to freedom of expression and public participation.' The statement voiced deep concern over the decline in Soueif's health. 'In her perseverance,' it read, 'resounds the perseverance of hundreds of families worn down by imprisonment, and the stories of parents, siblings and children who have tried to make their voices heard only to be met with a wall of silence.' Soueif has made repeated appeals, both to the Public Prosecution and to leaders in both Egypt and the United Kingdom, where she and her family hold second nationality. In their statement, which remained open for additional signatories, the former prisoners called on authorities to 'reconsider the cases of all political prisoners.' 'We urge the relevant authorities in the Egyptian state to act with the wisdom and responsibility that this critical historical moment demands — and to release Alaa Abd El Fattah, in whatever form they see fit, in a way that befits a strong nation capable of correcting its course without hesitation,' the statement read. The signatories argued that releasing Abd El Fattah would do no harm to the state, just as their own releases 'have not posed any threat to public safety.' Instead, their release was welcomed both domestically and internationally as 'a reflection of a maturing state that comprehends the moment,' the statement added. Soueif, a mathematics professor at Cairo University, is on hunger strike to call for her son's release in 2024. The writer's sentence was due to come to an end in September but prosecutors refused the families' petitions to credit the two years he spent in remand detention toward his final sentence. The Civil Democratic Movement, a coalition of liberal parties, also called for Abd El Fattah's release at a press conference held Sunday at the headquarters of the Conservative Party. The politicians said that the power to release Abd El Fattah lay in the President's hands, urging him to include Abd El Fattah, alongside others imprisoned for freedom of expression, in general amnesty lists released for Eid al-Adha. Lawyer Suzanne Nady, who was in attendance, questioned what more must happen before Egyptian authorities begin upholding the law. 'We've already exhausted every peaceful route,' she said. Cairo University students submitted their own urgent appeal on Sunday to university president Mohamed Samy Abdel Sadek to intervene and save Soueif's life, who they said 'continued to fulfill her academic and teaching responsibilities at the university with unwavering dedication, up until the moment she departed for London.' The statement, a copy of which Mada Masr reviewed, called for Abdel Sadek to address the president and relevant authorities to secure Abd El Fattah's release 'in recognition of what [Soueif] offered and continues to offer to the university and Egypt's scientific community.' Over the past months, Soueif has repeatedly appealed to authorities in both Egypt and the United Kingdom. But 'nothing has changed,' Soueif said in a statement two weeks ago, announcing her decision to resume a full hunger strike after she had temporarily increased her intake to include a 300-calorie liquid supplement daily in March at the advice of doctors. British Prime Minister Keir Starmer last contacted President Abdel Fattah al-Sisi regarding Abd El Fattah's case on May 22. Though Soueif acknowledged Starmer's intentions in her announcement that she would resume a full hunger strike, she concluded that 'nothing is happening' to release her son. 'We have used up more days than we ever thought we had. We need Alaa released now.'
CairoScene
15 hours ago
- CairoScene
Josour Schools to Launch New Neurodiversity Campus in Riyadh
Josour Schools opens this September in Riyadh's Roshn Sedra 1, offering tailored education for neurodiverse children. Josour Schools is set to launch a new specialised school for neurodiverse children aged three to nine in Riyadh's Roshn Sedra 1 community this September. The school is being established through a partnership between Saudi-based Josour Company and UK-headquartered CareTech. The campus will integrate education, therapy, and family support within a small-class environment. It will follow a British curriculum adapted to align with local cultural values and is designed to support Saudi Arabia's Vision 2030 objectives around inclusive education. The school will be staffed by educators trained in the UK and supported by therapists working in coordination with international specialists. According to CareTech, the school will also benefit from access to its broader network of 47 schools and 550 specialist services across the United Kingdom. Admissions are currently open for the 2025 academic year.
